AriBio draws $8.65M from China's Fosun Pharma ahead of key Alzheimer's readout
What's the deal? AriBio has secured US$9.62M from Chinese pharmaceutical company Fosun Pharma in a post-IPO equity investment. It is the first installment of a US$35.6M third-party rights offering the two companies agreed in July.
What does AriBio do? The South Korean biotech is developing AR1001, an oral Alzheimer's disease treatment candidate. Fosun holds the global rights to the drug under an exclusive licensing deal signed in May.
Why now? The payment lands weeks before AriBio presents Phase 3 trial results (POLARIS-AD) at the Alzheimer's Clinical Trials Conference in Boston on November 16. The company expects the funding to accelerate preparations for approval and commercialisation once results are in.
What's the endgame? AriBio plans to use the funds to prepare for AR1001's global commercialisation and to develop later-stage pipelines, including AR1005 for Lewy body dementia and its HERJION electronic medicine. Once a second installment of US$26M is finalised, Fosun would take roughly 5% of AriBio, becoming its third-largest shareholder after AriBio Holdings and Samjin PharmDealroom has a profile for this one. Try Dealroom →.
What could go wrong? The investment deepens an existing partnership, but it is not proof that AR1001 works. The Phase 3 results remain the key test, and the second tranche is still pending.
"We will continue our steps toward becoming a global biopharmaceutical company, leveraging our strengthened financial foundation and global partnerships," said chief executive officer Jung Jae-jun.
The signal: A global pharma taking a direct equity stake so soon after licensing a drug is unusual — companies typically wait to see development progress. For AriBio, it is strategic backing at a pivotal moment, as it approaches a major clinical readout and reworks its listing plans.
Read more: chosun.com
Image credit: zhouxuan12345678
